AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9432341
Drug: RBC800 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC800 + CLAR (Ranitidine bismuth citrate 800 mg bid with clarithromycin 250 mg qid for 14 days)
Trial: 9432341
Drug: RBC400 (Ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC400 (Ranitidine bismuth citrate 400 mg bid alone for 4 weeks)
Trial: 7523450
Drug: 0.30 mg
RxNorm normalized name: Corona Multi-Purpose 0.30 MG/MG Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg DEP nasal challenge
Trial: 30830474
Drug: UDCA 400
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 400 mg daily for 2 weeks
Trial: 30830474
Drug: UDCA 800
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 800 mg daily for 2 weeks
Trial: 30830474
Drug: UDCA 1200
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 1200 mg daily for 2 weeks
Trial: 26749073
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (EPA + DHA; 8-10 g over 2-5 days preoperatively, then 2 g/day postoperatively)
Trial: 17392540
Drug: Metformin (500-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500-1000 mg twice daily)
Trial: 15356074
Drug: rhIGF‐I/IGFBP‐3 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I/IGFBP‐3 (0.1 mg/kg.d)
Trial: 15356074
Drug: rhIGF‐I/IGFBP‐3 (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I/IGFBP‐3 (0.4 mg/kg.d)
Trial: 15356074
Drug: rhIGF‐I/IGFBP‐3 (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐I/IGFBP‐3 (0.8 mg/kg.d)
Trial: 11591843
Drug: Pulsed IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed IV methylprednisolone (IVMP) - 1 g/day for 5 days every 4 months for 3 years, then every 6 months for 2 years
Trial: 8059023
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEpo) treatment
Trial: 8059023
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hemodialysis and rHuEpo
Trial: 28780563
Drug: Multi-modal support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-modal support service programme including mail-delivered cognitive behavioural therapy, telephone-delivered group counselling, and education on community services/resources.
Trial: 26505201
Drug: Yoga program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga program (60-minute session twice a week for 8 weeks)
Trial: 24565712
Drug: FENO-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FENO-guided treatment
Trial: 18463442
Drug: Pentagastrin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentagastrin (6 microg/kg) during placebo treatment
Trial: 18463442
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg bid) treatment
Trial: 15345738
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (800 mg/day) combined with testosterone injections (100 mg/week)
Trial: 15345738
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (800 mg/day) combined with placebo injections
Trial: 15345738
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (800 mg/day) combined with resistance training
Trial: 15345738
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (800 mg/day) combined with resistance training and testosterone
Trial: 8803642
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo injections)
Trial: 9071805
Drug: Experimental stimuli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental stimuli (combinations of corn syrup and water with viscosities ranging from 2 to 2,240 cP)
Trial: 2429334
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tiropramide per day
Trial: 2429334
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg imecromone per day
Trial: 31340206
Drug: Neo-adjuvant Chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant Chemoradiation Therapy (NACRT)
Trial: 31340206
Drug: Neo-adjuvant Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant Chemotherapy (NAC)
Trial: 27678438
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (3 g/day) with a low-calorie diet
Trial: 27678438
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g/day) with a low-calorie diet
Trial: 20235203
Drug: Varicella vaccine
RxNorm normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varicella vaccine (VV)
Trial: 18514633
Drug: Amino acids
RxNorm normalized name: Amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acids (AAs) supplementation, 70.6 kcal/day (8 g of AA snacks) given at 10.00 am and 5.00 pm
Trial: 15885167
Drug: Rhubarb administration
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb administration before operation and at 1 day and 2 days after operation
Trial: 15885167
Drug: Rhubarb administration
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb administration
Trial: 15885167
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no rhubarb administration)
Trial: 11952024
Drug: Emedastine difumarate
RxNorm normalized name: Emedastine Difumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emedastine difumarate 0.05% ophthalmic solution
Trial: 2277475
Drug: Streptokinase (1,000,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (1,000,000 units intravenously) followed by intravenous heparin for 5-7 days
Trial: 7157926
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no streptokinase treatment)
Trial: 30777957
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus dose of intravenous cefazolin 1 g at surgery (Group A)
Trial: 30777957
Drug: Oral cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cephalexin 500 mg postoperatively twice a day for 5 days (Group B)
Trial: 21372561
Drug: Gentamicin/heparin (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin/heparin (group A)
Trial: 21372561
Drug: Heparin (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (group C)
Trial: 17264338
Drug: Oral uracil/ftorafur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral uracil/ftorafur (UFT) plus leucovorin (LV)
Trial: 9233710
Drug: pp65 antigenemia-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pp65 antigenemia-guided early ganciclovir treatment
Trial: 8013155
Drug: Neoadjuvant combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant combination therapy with flutamide and Lupron for 3 months
Trial: 3626867
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms Cr + 100 mg nicotinic acid
Trial: 3626867
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg nicotinic acid
Trial: 21546629
Drug: CEM‐102 loading‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEM‐102 loading‐dose regimen (1500 mg twice per day on day 1 followed by 600 mg twice per day)
Trial: 21546629
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg twice per day)
Trial: 9029449
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) + 2.5 mg chlorhexidine (CHX)
Trial: 3552680
Drug: Verapamil 80
RxNorm normalized name: verapamil 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 80 mg tds
Trial: 3552680
Drug: Verapamil 40
RxNorm normalized name: verapamil 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 40 mg tds
Trial: 3552680
Drug: Verapamil (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (higher doses)
Trial: 21353251
Drug: Left atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left atrial volume index ≥40 mL/m²
Trial: 21353251
Drug: Left atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left atrial volume index <40 mL/m²
Trial: 19039965
Drug: Propofol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (target controlled infusion; 2-3 mcg x ml(‐1))
Trial: 12689610
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of 50 nmol of Neuropeptide Y (NPY)
Trial: 10513708
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 1 g/kg daily on 2 consecutive days
Trial: 10513708
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution given in the same manner as IVIG)
Trial: 27578972
Drug: Home-based spirometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based spirometry measurements during continued fluticasone propionate treatment for 52 weeks
Trial: 27578972
Drug: In-clinic spirometry
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-clinic spirometry measurements during continued fluticasone propionate treatment for 52 weeks
Trial: 19320650
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium tolerance test (OCTT) with a 10-mmol calcium dose
Trial: 16053953
Drug: Eplerenone 25
RxNorm normalized name: eplerenone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 25 mg/day
Trial: 12493339
Drug: Cilomilast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilomilast (10 mg twice daily) plus nebulised salbutamol (2.5 mg)
Trial: 12493339
Drug: Cilomilast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilomilast (10 mg twice daily) plus nebulised placebo
Trial: 12493339
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus nebulised salbutamol (2.5 mg)
Trial: 7659146
Drug: Trimethoprim 80
RxNorm normalized name: trimethoprim 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 80 mg-sulfamethoxazole 400 mg (TMP-SMX) orally twice per day for one month
Trial: 7659146
Drug: Trimethoprim 80
RxNorm normalized name: trimethoprim 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 80 mg-sulfamethoxazole 400 mg (TMP-SMX) orally twice per day for one month + frequent ejaculation (at least once every three days) for one month
Trial: 1270775
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral hygiene therapy three times weekly for 5 weeks
Trial: 31307501
Drug: LED-RL (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED-RL (all doses)
Trial: 23485539
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of daclizumab (1 mg/kg) before and 14 days after transplantation
Trial: 23485539
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment protocol only
Trial: 21644317
Drug: Santong tuina
RxNorm normalized name: santonin
DrugBank: Santonin (DB19377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Santong tuina therapy
Trial: 21644317
Drug: Conventional tuina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tuina therapy
Trial: 19250106
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.0-3.5)
Trial: 17026489
Drug: RSG/MET fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG/MET fixed-dose combination therapy (initial dose 2 mg/500 mg, uptitrated to 8 mg/2000 mg)
Trial: 17026489
Drug: RSG/MET fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG/MET fixed-dose combination therapy
Trial: 17026489
Drug: MET monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET monotherapy (initial dose 500 mg, uptitrated to 2000 mg)
Trial: 17026489
Drug: RSG monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG monotherapy (initial dose 4 mg, uptitrated to 8 mg)
Trial: 9073134
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal nitroglycerin (5 mg/day)
Trial: 9073134
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal nitroglycerin plus spironolactone (100 mg/day)
Trial: 9073134
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal nitroglycerin
Trial: 9073134
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal nitroglycerin plus spironolactone
Trial: 105386
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition with a mixture of carbohydrate and essential L-amino acids
Trial: 31701308
Drug: Dexmedetomidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.3 µg/kg)
Trial: 22712503
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) with medical treatment as usual, 8 sessions
Trial: 22712503
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received only medical treatment as usual
Trial: 18301120
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (e.g., olanzapine, risperidone, quetiapine)
Trial: 18301120
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors and serotonin‐noradrenaline reuptake inhibitors
Trial: 12592551
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of methylprednisolone intravenously at the end of the operation and 12 and 24 hours later (group II)
Trial: 10560385
Drug: HAI chemotherapy
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI chemotherapy (12 g of 5‐FU administered in 6 weeks)
Trial: 10560385
Drug: HAI chemotherapy
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI chemotherapy (1,000-1,500 mg/w of 5‐FU)
Trial: 7472904
Drug: fermented whey-adapted
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fermented whey-adapted infant formula containing viable bifidobacteria (10^6/g of powder)
Trial: 2337034
Drug: Aspirin 60
RxNorm normalized name: aspirin 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 60 mg/kg/day for 7 days starting on the third postoperative day (group 1, 32 patients)
Trial: 2337034
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin (group 2, 42 patients)
Trial: 2337034
Drug: Aspirin 60
RxNorm normalized name: aspirin 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 60 mg/kg/day for 7 days
Trial: 29802215
Drug: Aspirin prophylaxis
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin prophylaxis
Trial: 28952201
Drug: Aprepitant plus
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant plus palonosetron (administered with dexamethasone)
Trial: 25546165
Drug: Triflusal (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal (900 mg) under fasting condition
Trial: 25546165
Drug: Triflusal (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal (900 mg) under fed condition (after a high-fat meal)
Trial: 21161171
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (machine not turned on)
Trial: 15075653
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BoTx) injection, 8 to 100 units injected twice, a month apart at the esophagogastric junction.
Trial: 3299178
Drug: Alprazolam 0.25
RxNorm normalized name: alprazolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.25 mg administered three times daily from cycle day 20 until the second day of menstruation, tapered by one tablet per day thereafter.
Trial: 3299178
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered three times daily from cycle day 20 until the second day of menstruation, tapered by one tablet per day thereafter.
Trial: 27169838
Drug: Orange maizemeal
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange maizemeal (200 g, 6 days/week for 6 months)
Trial: 27169838
Drug: White maizemeal
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White maizemeal (200 g, 6 days/week for 6 months)
Trial: 25035292
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg intravenous every 3-4 weeks for six doses, then every 3 months for eight doses, followed by every 6 months for five doses, for a total of 5 years)
Trial: 10689845
Drug: Nicorandil infusion
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil infusion
Trial: 1482152
Drug: TMP-SMX (160:800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP-SMX (160:800 mg twice daily for six doses)
Trial: 1482152
Drug: Single large
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single large dose of TMP-SMX (320:1,600 mg)
Trial: 1482152
Drug: Large loading
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large loading dose (320:1,600 mg) followed by standard doses (160:800 mg twice daily for five doses)
Trial: 1482152
Drug: Loperamide (4-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (4-mg loading dose; 2 mg after each loose stool, not to exceed 16 mg/day for 3 days)
Trial: 6541200
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc as an adjunct to dapsone
Trial: 30556410
Drug: Endoventricular patch
RxNorm normalized name: cerliponase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoventricular patch
Trial: 3885984
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg domperidone
Trial: 19555938
Drug: Water infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water infusion in lieu of air insufflation
Trial: 17230049
Drug: Volition group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volition group therapy in addition to standard cognitive behavioral therapy (VG)
Trial: 17230049
Drug: Standard cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive behavioral therapy (SG)
Trial: 15100505
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of 99mTc-tetrofosmin
Trial: 15100505
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 99mTc-tetrofosmin
Trial: 11581449
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 1 to 2 ppm (low-dose group)